TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03269617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacteriophage mixture
Description: Four bacteriophage strains: LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo control capsule consisting of rice maltodextrin
Study: NCT01181544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heparin dose titration
Description: Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
Study: NCT02428049

Intervention type: RADIATION
Intervention: Stereotactic or conventional radiotherapy and chemotherapy in curative intent
Study: NCT03574142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova
Description: A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.
Study: NCT00793624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for comparison Formoterolon safety and efficacy in COPD patients
Study: NCT02161484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Lumbar Plexus Block
Description: Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Lumbar Plexus Block
Description: Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parasacral Nerve Block
Description: A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacine 0.2%
Description: Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacine 0.2%
Description: Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625%
Description: In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.0625%
Description: In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
Study: NCT01531530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 1208S, a Shigella flexneri 2a live, oral vaccine
Description: The vaccine is mixed with salt water and given by mouth.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn starch and baking soda are mixed with salt water and given by mouth.
Study: NCT00604942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heller's Myotomy
Description: Long vs Short Heller's Myotomy for Achalasia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nissen Fundoplication
Description: Partial vs Full Fundoplication for GORD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domperidone or esomeprazole (Conservative management)
Description: Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Esomeprazole vs no esomeprazole for GORD not referred for surgery
Study: NCT03091036

Intervention type: OTHER
Group type: OTHER
Intervention: Proactive healthcare intervention
Description: There is an intervention in the coordination of health resources, and monitoring readmissions and know the benefit in total cost of care in 4 month.
Study: NCT03431025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensors and biofeedback
Description: Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
Study: NCT04722367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Pedagogy and Mindfulness
Description: Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
Study: NCT01355198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cysteine (as n-acetylcysteine) and glycine
Description: Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cysteine/glycine
Description: Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
Study: NCT00351741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation - High Frequency Percussive Ventilation
Description: Ventilatory support delivering high frequency percussive ventilation using the Volumetric Diffusive Respirator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation - ARDSnet
Description: Respiratory support with a conventional mode of ventilation using a conventional ventilator (Draeger Evita XL)
Study: NCT03078179

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Commercial Dairy Cow Milk
Description: After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercial Cow Milk with Probiotic
Description: The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
Study: NCT01438294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video game group
Description: The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise group
Description: A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
Study: NCT04271839

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fluticasone/formoterol k-haler (medium strength)
Description: 2 inhalations every 12 hours

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (ICs/LABA high strength)
Description: Depend of the ICs/LABA combination
Study: NCT03775863

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation for patients with hepatocellular carcinoma

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation for patients with hepatocellular carcinoma
Study: NCT03491748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules
Study: NCT03775863

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation for patients with hepatocellular carcinoma
Study: NCT02468154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom made splint
Description: Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard off-load plaster cast
Description: To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
Study: NCT00342563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecamylamine
Description: mecamylamine 10mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecamylamine
Description: mecamylamine 10mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00271011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan.
Description: Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1\*28 allele will receive irinotecan 110 mg/m2.
Study: NCT04546529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-spinal Magnetic Stimulation (TsMS)
Description: Patients undergoing real TsMS with coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Trans-spinal Magnetic Stimulation (TsMS)
Description: Patients undergoing placebo TsMS with coil
Study: NCT01915667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg GLPG0634 as capsules, fasted
Description: single oral dose of 200 mg GLPG0634 given as capsules in fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg GLPG0634 as tablets, fasted
Description: single oral dose of 200 mg GLPG0634 given as tablets in fasted condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg GLPG0634 as tablets, fed
Description: single oral dose of 200 mg GLPG0634 given as tablets in fed condition
Study: NCT02131818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will be received placebo 2 capsules orally bid pc for 5 days
Study: NCT04109287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVITIVE® device
Description: The REVITIVE® device applies neuromuscular electrical stimulation to the soles of the feet, causing the muscles of the leg to contract and relax, thus improving blood circulation through the legs.
Study: NCT02643849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Spanner Temporary Prostatic Stent
Study: NCT01858779

Intervention type: BEHAVIORAL
Intervention: Measurement of peripheral pulse
Description: All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.

Intervention type: DEVICE
Intervention: 72h holter ECG
Description: All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
Study: NCT04001387

Intervention type: PROCEDURE
Intervention: Real-time ultrasound guided spinal anesthesia
Description: The neuraxial US scan will be performed with the patient in the lateral position with the hip and knees flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance using dynamic needle tip positioning to administer the spinal anesthetic.
Study: NCT01044290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life Completion
Description: Subjects discussed life review, issues of forgiveness and heritage and legacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Subjects listened to a non-guided relaxation CD
Study: NCT04606485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupressure
Description: Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.
Study: NCT02609100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video Capsule Endoscopy
Description: Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 X 2.5 cm 'pill' containing a camera
Study: NCT04025931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide and toripalimab
Description: The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
Study: NCT01298726

Intervention type: OTHER
Group type: OTHER
Intervention: PHARMACEUTICAL CARE
Description: The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.

Intervention type: OTHER
Group type: OTHER
Intervention: HEALTH USUAL CARE
Description: Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
Study: NCT02768116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sirolimus Drug-eluting Stent via Active Transfer of Plaque

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus Drug-eluting Stent implantation via Provisional T Stenting
Study: NCT00892398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard post-operative care after trabeculectomy with mitomycin C
Study: NCT01390883

Intervention type: DRUG
Intervention: Fondaparinux Sodium
Study: NCT02547857

Intervention type: OTHER
Intervention: Pelvic US
Description: To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
Study: NCT03940430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
Study: NCT03724006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: The intervention, prepared by a multidisciplinary team, will consist of two 90 minutes collective sessions (max. 8 families). Sessions will consist of lectures, group discussion and relaxation. The program includes content on the effects of a diagnosis of a congenital anomaly on a child in the parents and in the family, stages of mourning, adaptation process, coping strategies, legislative framework and social protection. This is a non-specific intervention for CHD, where the main focus is the diagnosis of a congenital anomaly.~In second session, written support material will be distributed. Participants will be asked to practice relaxation in the next 4 weeks.